Evidence map›Paper›PMID 27297094›Full record

ArticleJournal of molecular biology2016

Differential Contributions of Ubiquitin-Modified APOBEC3G Lysine Residues to HIV-1 Vif-Induced Degradation.

Tiffany Turner, Qiujia Shao, Weiran Wang, Yudi Wang, Chenliang Wang, Ballington Kinlock, Bindong Liu

Abstract read
In one paragraph

Article in Journal of molecular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Tiffany TurnerCenter for AIDS Health Disparities Research, Department of Microbiology and Immunology, Meharry Medical College, Nashville, TN 37208, USA.
Qiujia ShaoCenter for AIDS Health Disparities Research, Department of Microbiology and Immunology, Meharry Medical College, Nashville, TN 37208, USA.
Weiran WangCenter for AIDS Health Disparities Research, Department of Microbiology and Immunology, Meharry Medical College, Nashville, TN 37208, USA; National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, Jilin Province 130000, People's Republic of China.
Yudi WangCenter for AIDS Health Disparities Research, Department of Microbiology and Immunology, Meharry Medical College, Nashville, TN 37208, USA.
Chenliang WangCenter for AIDS Health Disparities Research, Department of Microbiology and Immunology, Meharry Medical College, Nashville, TN 37208, USA.
Ballington KinlockCenter for AIDS Health Disparities Research, Department of Microbiology and Immunology, Meharry Medical College, Nashville, TN 37208, USA.
Bindong LiuCenter for AIDS Health Disparities Research, Department of Microbiology and Immunology, Meharry Medical College, Nashville, TN 37208, USA. Electronic address: bliu@mmc.edu.
Meharry Medical College · US

Funding

The RCMI Program in Health Disparities Research at Meharry Medical College - SupplementU54MD007586 · NIMHD · MEHARRY MEDICAL COLLEGE · PI Maureen Sanderson · 2017 to 2026
$48.2M
Tennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI John Koethe · 2015 to 2026
$27.5M
THE MEHARRY RISE INITIATIVER25GM059994 · NIGMS · MEHARRY MEDICAL COLLEGE · PI MOTLEY-JOHNSON, EVANGELINE D · 1999 to 2021
$23.0M
Meharry RCMI Program in Women's Health ResearchG12MD007586 · NIMHD · MEHARRY MEDICAL COLLEGE · PI HILDRETH, JAMES E · 2012 to 2016
$7.8M
MOLECULAR PARASITOLOGY TRAINING PROGRAMT32AI007281 · NIAID · MEHARRY MEDICAL COLLEGE · PI NDE, PIUS N · 1985 to 2025
$3.2M
Characterizing a small molecule of Streptococcus cristatus for HIV drug designSC1GM089269 · NIGMS · MEHARRY MEDICAL COLLEGE · PI LIU, BINDONG · 2009 to 2019
$2.6M
NIAID NIH HHS P30 AI110527NIAID NIH HHS T32 AI007281NIGMS NIH HHS R25 GM059994NIGMS NIH HHS SC1 GM089269NIMHD NIH HHS G12 MD007586
6 · The paper itself

Abstract

Apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (A3G) is a host restriction factor that impedes HIV-1 replication. Viral integrity is salvaged by HIV-1 virion infectivity factor (Vif), which mediates A3G polyubiquitination and subsequent cellular depletion. Previous studies have implied that A3G polyubiquitination is essential for Vif-induced degradation. However, the contribution of polyubiquitination to the rate of A3G degradation remains unclear. Here, we show that A3G polyubiquitination is essential for degradation. Inhibition of ubiquitin-activating enzyme E1 by PYR-41 or blocking the formation of ubiquitin chains by over-expressing the lysine to arginine mutation of ubiquitin K48 (K48R) inhibited A3G degradation. Our A3G mutagenesis study showed that lysine residues 297, 301, 303, and 334 were not sufficient to render lysine-free A3G sensitive to Vif-mediated degradation. Our data also confirm that Vif could induce ubiquitin chain formation on lysine residues interspersed throughout A3G. Notably, A3G degradation relied on the lysine residues involved in polyubiquitination. Although A3G and the A3G C-terminal mutant interacted with Vif and were modified by ubiquitin chains, the latter remained more resistant to Vif-induced degradation. Furthermore, the A3G C-terminal mutant, but not the N-terminal mutant, maintained potent antiviral activity in the presence of Vif. Taken together, our results suggest that the location of A3G ubiquitin modification is a determinant for Vif-mediated degradation, implying that in addition to polyubiquitination, other factors may play a key role in the rate of A3G degradation.

Indexed as

Protein Processing, Post-TranslationalAPOBEC-3G DeaminaseLysineProteolysisUbiquitinvif Gene Products, Human Immunodeficiency VirusAPOBEC-3G DeaminaseAPOBEC3G protein, humanLysineUbiquitinvif Gene Products, Human Immunodeficiency Virusvif protein, Human immunodeficiency virus 1APOBEC3G lysine free mutanthost restriction factorpolyubiquitinationproteasomal degradationubiquitin-activating enzyme E1 inhibitor PYR-41

Identifiers

PMID27297094
PMCPMC5010486
OpenAlexW2414287120

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.